IA
KROS icon

IFP Advisors’s Keros Therapeutics KROS Stock Holding History

IFP Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.2K Buy
3,013
+161
+6% +$1.79K ﹤0.01% 2676
2026
Q1 		$31.5K Buy
2,852
+2,771
+3,421% +$42.8K ﹤0.01% 2519
2025
Q4 		$1.65K Buy
81
+52
+179% +$912 ﹤0.01% 3905
2025
Q3 		$459 Buy
29
+28
+2,800% +$414 ﹤0.01% 4196
2025
Q2 		$521 Buy
+1
New +$14 ﹤0.01% 4426
2025
Q1 		– Sell
-1
Closed -$16 – 4497
2024
Q4 		$16 Buy
+1
New +$52 ﹤0.01% 4484

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

IFP Advisors's KROS Position: Q2 2026 in Review

IFP Advisors increased its Keros Therapeutics (KROS) stake by 5.6% in Q2 2026, buying an estimated $1.79K and bringing the position to 3,013 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

IFP Advisors first reported a position in KROS in Q4 2024 and has held it in 6 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • IFP Advisors held 3,013 shares of Keros Therapeutics worth $32.2K as of Q2 2026.
  • IFP Advisors bought 161 Keros Therapeutics shares in Q2 2026, an estimated $1.79K.
  • Keros Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2676 holding.
  • IFP Advisors first reported a position in Keros Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.